Verve Therapeutics, Inc.
VERV · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 1.44 | 0.00 | 0.00 |
| FCF Yield | -7.16% | -8.62% | -9.90% | -8.38% |
| EV / EBITDA | -10.82 | -7.13 | -5.84 | -6.13 |
| Quality | ||||
| ROIC | -6.41% | -8.98% | -8.88% | -8.65% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.90 | 0.82 | 0.79 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 161.21% | 155.39% | 197.24% | 2,743,322.30% |
| Free Cash Flow Growth | 31.17% | -4.17% | -15.38% | 19.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.80 | 1.89 | 1.59 | 1.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3.82 | 22.40 | 34.45 | 40.88 |